inTervieW - Green Cross Publishing

More documents

Recommendations

Info

INDICATED FOR MILD TO MODERATE PAIN RELIEF Effective Pain Relief including: Headache Migraine Headache Dental Pain Period Pain Fever ABBREVIATED PRESCRIBING INFORMATION. Please refer to the Summary of Product Characteristics before dispensing: Buplex 200 mg Film-coated Tablets. Indications: Mild to moderate pain, such as headache including migraine headache, dental pain. Primary dysmenorrhoea. Fever. Dosage: Short-term use only, not longer than 7 days. Dose depends on the patient’s age and body weight. Tablet should be swallowed with a glass of water during or after a meal. Mild to moderate pain and fever: Adults and adolescents older than 12 years (≥40 kg): 200-400 mg as a single dose or 3-4 times a day every 4 to 6 hours. In migraine, 400 mg as a single dose, if necessary 400 mg every 4-6 hours. Maximum daily dose: 1200 mg. Children 6-9 years (20-29 kg): 200 mg 1-3 times a day every 4 to 6 hours as required. Maximum daily dose: 600 mg. Children 10-12 years (30-40 kg): 200 mg 1-4 times a day every 4 to 6 hours as required. Maximum daily dose: 800 mg. Primary dysmenorrhoea: Adults and adolescents over 12 years of age: 200-400 mg 1-3 times a day, every 4-6 hours, as required. Maximum daily dose: 1200 mg. Contraindications: Hypersensitivity, Last trimester of pregnancy, History of gastrointestinal bleeding or perforation related to previous NSAID therapy, Active or recurrent peptic ulcer/haemorrhage, Severe hepatic or renal insu� ciency, Severe heart failure or coronary heart disease, Signi� cant dehydration, Cerebrovascular or other active bleeding, Dishaematopoiesis of unknown origin, Children younger than 6 years of age. Warnings and Precautions: Use the lowest e� ective dose for the shortest duration necessary. Symptoms of an infection may be masked. Avoid concomitant use with other NSAIDs, including COX-2 inhibitors. GI bleeding, ulceration and perforation may occur with or without warning symptoms or previous history of GI events. Consider combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) for at risk patients. NSAIDS should be used with caution in patients with a history of peptic ulcer, GI bleeding, intestinal in� ammation, hepatic, renal or cardiac insu� ciency, hypertension, congestive heart failure, disturbed haematopoiesis, blood coagulation defects, respiratory disorders and immediately after surgical intervention. All patients, particularly the elderly and patients with impaired hepatic and renal function, on long term NSAID treatment should be kept under regular surveillance with monitoring of renal, cardiac and hepatic function and of haematological parameters. High dose and long term use may be associated with a small increased risk of arterial thrombotic events. Careful consideration before long term use in patients with cardiovascular disease or risk factors. Discontinue at � rst sign of skin rash, mucosal lesion or other sign of hypersensitivity. May impair female fertility. Strict consideration should be given to the bene� t-risk ratio in the following conditions: SLE or other autoimmune diseases, Congenital disturbance of porphyrin metabolism, First and second trimesters of pregnancy and Lactation. Interactions: Other NSAIDs; Anticoagulants; Ticlopidine; Methotrexate; Moclobemide; Phenytoin; Lithium; Cardiac glycosides; Diuretics and antihypertensives; Captopril; Aminoglycosides; SSRIs; Ciclosporin; Cholestyramine; Tacrolimus; Zidovudine; Ritonavir; Mifepristone; Probenecid; Sul� npyrazone; Quinolone antibiotics; Sulphonylureas; Corticosteroids; Anti-platelet aggregation agents; Alcohol; Bisphosphonates; Oxpentifylline; Baclofen. Side E� ects: Headache, somnolence, vertigo, fatigue, agitation, dizziness, insomnia, irritability, heartburn, nausea, vomiting, diarrhoea, � atulence, constipation, dyspepsia, abdominal pain, gastrointestinal ulcers, sometimes with bleeding and perforation, occult blood loss which may lead to anaemia, melaena, heamatemesis, ulcerative stomatitis, colitis, exacerbation of in� ammatory bowel disease and Crohn’s disease, complications of colonic diverticula. Shelf Life: 2 years. Pack Sizes: Blister: 12, 24 & 50 � lm-coated tablets. Marketing Authorisation Holder: Actavis Group PTC ehf, Reykjavikurvegi 76-78, 220 Hafnar� ordur, Iceland. Marketing Authorisation Number: PA 1380/87/1. Legal Category: Product not subject to medical prescription. Retail sale through pharmacies only. Further information including the SPC is available on request from Actavis Ireland Limited, Euro House, Little Island, Co. Cork or email: contact@actavis.ie. Information about adverse event reporting can be found on the IMB website (www.imb.ie) or by contacting Actavis Ireland Limited. Date of Generation of API: January 2010. Date of Preparation: August 2010. FADHCP-02710. NEW
The independenT monThly foR iRish phaRmacisTs issue 10 volume 12 • novemBeR 2010 4 neWs 10 LeTTers Reaction to Prof Weedle’s comments on codeine 14 eu neWs 16 HerbaL MeDiCine The merits of Christmas cooking Des Corrigan 18 inTervieW Masters of Pharmacy ingrid Hook – teaching legend 20 THe CoaLFaCe Are we producing pharmacists for export? David Jordan Irish Pharmacist is published by GreenCross Publishing, 7 Adelaide Court, Adelaide Road, Dublin 2. Tel: 01 418 9799. Fax: 01 478 9449. maura@greencrosspublishing.ie www.greencrosspublishing.ie Irish Pharmacist endeavours to ensure accuracy of information given and of claims made in articles and advertisements. Nevertheless, no responsibility is accepted in respect of such information or claims. Any opinions expressed by contributors are entirely their own and do not purport to be the views of Irish Pharmacist. © Copyright GreenCross Publishing 2010 No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means – electronic, mechanical or photocopy recording or otherwise – whole or in part, in any form whatsoever for advertising or promotional purposes without the prior written permission of the publishers. GreenCross Publishing is a recently established publishing house which is jointly owned by Graham Cooke and Maura Henderson. Between them Graham and Maura have over 30 years experience working in healthcare publishing. Their stated aim is to publish titles which are incisive, vibrant and pertinent to their readership. EDITOR: Maura Henderson DESIGn: Barbara Vasic REPORTER: June Shannon SUB-EDITOR: Tim Ilsley PUBlISHER: Graham Cooke PUBlISHER: Maura Henderson COnTRIBUTORS: Iain Cahill, Dr Des Corrigan, Garry Finnegan, David Jordan, Julian Judge, Fintan Moore, Terry McGuire, Cormac O’neill PHOTOGRAPHy: Audrey Hanley PRInTERS: newman Thomson ltd lETTERS TO THE EDITOR: maura@greencrosspublishing.ie Advertising: graham@greencrosspublishing.ie or 0872222221 22 vieW FroM above listening to your ‘difficult’ clients can be most rewarding Terry Maguire 24 LaW Treating children – the legal implications for pharmacists Cormac o'neill 26 FinanCe How safe are your investments? iain Cahill 28 CreaTive WriTing lefty Julian Judge Exputex 145x210 16/10/2008 10:51 Page 1 conTenTs Good News for chesty coughs Exputex Carbocisteine mucolytic syrup COMPLETE WITH CHILD RESISTANT TAMPER EVIDENT CAP SUGAR FREE ✓ Non drowsy ✓ Mentholated ✓ 300ml - the lowest cost sugar free carbocisteine mucolytic syrup (on a ml per ml basis 250mg/5ml) 1 Prescribing Information (Please refer to full Summary of Product Characteristics [SmPC]) Exputex 250mg/5ml Oral Solution Presentation: Carbocisteine provided as 250mg/5ml oral solution. Uses: As a mucolytic adjunct for respiratory tract disorders characterised by excessive or viscous mucous. Dosage and administration: Oral. Adults/Elderly: Three 5ml spoonfuls three times daily initially. Reduce to two 5ml spoonfuls three times daily when a satisfactory response has been obtained. Children: 6-12 years: 5ml spoonful (250mg) two to three times daily. 2-5 years: Half a 5ml spoonful (125mg) two to three times daily. Under 2 years: Not recommended. Contraindications: Hypersensitivity, patients with known active peptic ulceration. Special Warnings and Precautions: Patients with a history of peptic ulceration, avoid in patients with active ulceration, patients on a controlled sodium diet. Contains parahydroxybenzoates (E215, E217 and E219), sunset yellow FCF (E110) and ethanol. Interactions: None listed. Pregnancy and Lactation: Not recommended. Undesirable Effects: Nausea, headache, gastrointestinal upset and skin rash. Overdose: No experience. Serious effects not expected. Legal category: S1B(E) Product Authorisation number: PA 488/14/1. Product Authorisation holder: 30 e-PHarMaCy Depression – new campaign – something to sing about June shannon 32 Case sTuDy Cluster headache in a 24 year old woman Dr edward M o'sullivan 34 ProDuCTs 38 CrossWorD 38 CLassiFieDs anD reCruTiMenT 40 ouTsiDe eDge O’Sean’s Eleven Fintan Moore Monmouth Pharmaceuticals Limited, Hampshire International Business Park, Chineham, Basingstoke, Hampshire, RG24 8EP, UK. Distributed by: Cahill May Roberts, Pharmapark, Chapelizod, Dublin 20. Further information is available from: Shire Pharmaceuticals Limited, Hampshire International Business Park, Chineham, Basingstoke, Hampshire, RG24 8EP, UK. Tel: +44 1256 894000. Date of revision: June 2008. Exputex is a registered trademark of Shire US Inc. in Ireland. Adverse events should be reported to the Pharmacovigilance Unit at the Irish Medicines Board (IMB) (imbpharmacovigilance@imb.ie). Information about adverse event reporting can be found on the IMB website (www.imb.ie). Adverse events may also be reported to Shire Pharmaceuticals Ltd on +44 1256 894000. MONMOUTH P H A R M A C E U T I C A L S Monmouth Pharmaceuticals Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hants RG24 8EP 1 MIMS May 2008 Date of preparation: October 2008 IRE/EXP/08/0001
Page 1: issue 10 volume 12 novemBeR • 201
Page 5 and 6: NEW Won’t irritate your stomach l
Page 7 and 8: INTRODUCE YOUR CUSTOMERS TO A BRIGH
Page 9 and 10: Cymex Cream has a Triple Action For
Page 11 and 12: QicPOS.net Customer Loyalty Card Lo
Page 13 and 14: RoC ® SUBLIME ENERGY EYE EYELIDS
Page 16 and 17: 16 heRBal medicine Adding spice to
Page 18 and 19: 18 inTeRview In part two of our ser
Page 20 and 21: 20 opinion tHe CoAlfACe brain drain
Page 22 and 23: 22 PINIoN opinion vIew froM Above P
Page 24 and 25: 24 law lAw Treating children - the
Page 26: 26 finance How safe are your invest
Page 29 and 30: When it comes to Pharmacies, we do
Page 31 and 32: issue 10 volume 12 • novemBeR 201
Page 33 and 34: Date of preparation: April 2010 Tev
Page 36 and 37: 36 pRoducT news ‘Change one thing
Page 38 and 39: 38 classifieds/cRosswoRd DaTes For
Page 40: 40 opinion O’Sean’S eleven We

inTervieW - Green Cross Publishing

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?